WilmerHale represented the joint-book running managers in the public offering of 9,000,000 shares of common stock of Xeris Pharmaceuticals, Inc. at a price to the public of $4.15 per share. In addition, Xeris granted the underwriters an option for a period of 30 days to purchase up to an additional 1,350,000 shares of common stock at the public offering price, less the underwriting discount, which the underwriters exercised for 1,299,769 additional shares of common stock. The aggregate proceeds of the offering were approximately $42.7 million (before underwriting discounts and expenses). The transaction priced on February 11, 2020 and closed on February 14, 2020 and February 20, 2020.

The WilmerHale team consisted of Lisa Firenze, Bruce Manheim, Colleen Superko, Chip McCorkle, Howell Ma, Jenny Moore and Heidi Treiber.